From August 28th to 31st, POLYTECH’s annual distributor meeting took place in Bucharest, Romania, bringing together the key distributors of the leading European breast implant manufacturer.
Following three challenging years and a leadership change with the appointment of Professor Dr. Karsten Hemmrich as CEO, a fresh direction is taking shape for the German company. POLYTECH, the largest producer of breast implants in Europe with the broadest product portfolio, also welcomes a new CFO, Markus Neuhauser, who works closely with the CEO to lead the company’s strategic efforts.
One of the major announcements from the meeting is the significant ramp-up in breast implant production. The factory has switched to a three-shift system morning, afternoon, and evening to clear the current backlog of orders within the next four weeks. By early October, the company expects all regular products to be fully available again.
POLYTECH’s unique B-lite breast implants will also see a significant boost in production, with daily output reaching 250 implants starting in September. Looking ahead to 2026, B-lite implants will undergo further enhancements, featuring a new, softer filling and the elimination of the concave back design.
Another exciting introduction is the Opticon Plus implant, launching in September. Positioned between the existing Replicon and Opticon models, the Opticon Plus will have a slightly higher upper pole and will be available in both MESMO and Microthane versions. Additionally, custom sizers for the Opticon Plus will be introduced by 2025, with overall sizer production set to increase.
POLYTECH also announced the development of new tissue expanders with larger magnetic ports, available in both the Replicon and Opticon models. These will be distinguished by article codes starting with 46, as opposed to 40 for standard expanders, which will still be available. Known for their softer and more flexible feel compared to competitors like Mentor, POLYTECH’s expanders also allow for 20% overfilling, enabling a 300ml expander to be filled up to 360ml.
Globally, MESMO breast implants remain POLYTECH’s most popular product. Dr. Luana Clerico from POLYTECH’s medical department is set to present a retrospective study comparing MESMO implants with Mentor implants used in the CORE studies for breast reconstruction. The findings show that MESMO implants result in fewer complications.
Furthermore, a new publication is in progress comparing prepectoral reconstruction using Microthane implants without mesh versus subpectoral Microthane implants. Dr. Paolo Montemurro’s recent study also provides valuable insights for Motiva users, highlighting that POLYTECH’s MESMO implants offer significantly fewer complications and more predictable results.
Looking to expand into the U.S. market, initial discussions with the FDA have begun regarding the introduction of B-lite breast implants in America. Dael Govreen, POLYTECH’s product manager for B-lite, emphasized the strategic advantages of introducing these implants to the U.S. market.
The benefits of B-lite implants, which are 30% lighter than standard silicone implants, are numerous:
- Reduced risk of capsular contracture
- Less postoperative pain, resulting in lower pain medication usage
- Lower risk of implant rupture
- Reduced likelihood of implant displacement
- Decreased chance of ptosis (breast sagging)
- Minimal negative impact on surrounding tissues
- Reduced gel bleed, leading to a lower risk of conditions such as ASIA or BII syndrome
- Fewer wrinkles or folds due to the gel’s memory effect
- Enhanced radiotherapy options, allowing for lower doses.
With these exciting developments and innovations, POLYTECH is poised to lead the way in the breast implant industry.
